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Background: The rhizome of Hydnophytum formicarum Jack., a medicinal plant known in Thai as Hua-Roi-Roo, has
been used in Thai traditional herbal medicine for treatment of cancer. We assessed the ability of its ethanolic and
phenolic-rich extracts and its major phenolic compound, sinapinic acid, possessing histone deacetylase (HDAC)
inhibitory activity to inhibit proliferation of 5 human cancer cell lines.
Methods: HeLa cells were used to study HDAC inhibitory activity of the extracts, sinapinic acid, and a well-known
HDAC inhibitor sodium butyrate. Five human cancer cell lines and one non-cancer cell line were used to study
antiproliferative activities of the plant extracts, sinapinic acid and sodium butyrate, comparatively.
Results: Results indicated that ethanolic and phenolic-rich extracts of H. formicarum Jack. rhizome possessed both
antiproliferative activity and HDAC inhibitory activity in HeLa cells. Sinapinic acid, despite its lower HDAC inhibitory
activity than the well-known HDAC inhibitor sodium butyrate, inhibited the growth of HeLa and HT29 cells more
effectively than sodium butyrate. However, sinapinic acid inhibited the growth of HCT116 and Jurkat cells less
effectively than sodium butyrate. The non-cancer cell line (Vero cells) and breast cancer cell line (MCF-7 cells)
appeared to be resistant to both sinapinic acid and sodium butyrate. The growth inhibitory effects of the ethanolic
and phenolic-rich extracts and sinapinic acid in HeLa cells were mediated by induction of apoptosis.
Conclusions: The results of this study support the efficacy of H. formicarum Jack. rhizome ethanolic and phenolic-
rich extracts for the treatment of cervical cancer, colon cancer, and T- cell leukemia in an alternative medicine.
Further studies of other active ingredients from this plant are needed.
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In Thailand, a number of plants have been used in Thai
traditional herbal medicine for treatment of various malig-
nancies [1-5]. The rhizome of Hydnophytum formicarum
Jack., a medicinal plant known in Thai as Hua-Roi-Roo,
has been used against inflammation and cancer [1-3]. The
antiproliferative activities against human cancer cell lines
were described [4-7], however, the bioactive ingredients
underlying such activity remain to be explored. The
screening for histone deacetylase (HDAC) inhibitors from
Thai medicinal plants revealed that ethanolic crude extract
from the rhizome of H. formicarum Jack. possessed HDAC
inhibitory activity in vitro [8].
HDAC inhibitors belong to an exciting new class of
chemotherapeutic drug currently in several clinical trials
with promising results as anticancer agents [9-12]. In
general, HDAC inhibitors that act on zinc-dependent
HDAC isozymes have three structural characteristics: a
zinc-binding moiety, an opposite capping group, and a
straight chain alkyl, vinyl or aryl linker connecting the
zinc-binding moiety and the capping group [9]. Based
on their chemical structures, HDAC inhibitors can be
classified into four subtypes: (1) short chain fatty acid;
(2) hydroxamic acids; (3) benzamides; and (4) cyclic pep-
tides [13]. Although their mechanisms of action are
largely unknown, major consequences usually observed
upon treatment with HDAC inhibitors include growth
arrest, apoptosis, and inhibition of angiogenesis [9]. Be-
cause of their low toxicity, HDAC inhibitors constitute a
promising treatment for cancer therapy, especially in com-
bination with other chemotherapeutic agents [14,15].
HDAC inhibitor treatments resulted in cancer cell apop-
tosis due to a shift in the balance of pro- and anti-
apoptotic genes toward apoptosis [15].
In recent years, the development and search for novel
HDAC inhibitors have become a popular research focus
on discovering safe and effective anticancer agents [16,17].
One promising new source of HDAC inhibitors has been
discovered in plant secondary metabolites, specifically
phenolic compounds. The phenolic compounds of some
plants have been shown to possess HDAC inhibitory activ-
ity [16,18,19], however, the HDAC inhibitory activity of
phenolic compounds from H. formicarum Jack., which
may underpin its anticancer activity, has not yet been in-
vestigated. In this study, the biological evaluation of
HDAC inhibition, antiproliferation and apoptosis induc-
tion of cervical cancer cell line (HeLa cells) by ethanolic
crude extract and phenolic-rich extract of this plant were
reported. Moreover, the identification of sinapinic acid, a
known phenolic acid, as a novel HDAC inhibitor was
also demonstrated. Antiproliferative activity of sinapinic
acid compared with a well-known HDAC inhibitor so-
dium butyrate on five human cancer cell lines was
investigated.Methods
Materials
Dried rhizomes of H. formicarum Jack. were obtained
from a local herbal shop in Khon Kaen Province,
Thailand. The rhizomes were collected during March-
May 2008, from Narathiwat Province, Thailand. Taxo-
nomic identification was approved by the Forest
Herbarium, Department of National Parks, Wildlife and
Plant Conservation, Ministry of Natural Resources and
Environment, Bangkok, Thailand. A voucher specimen
(voucher number TS09001) is deposited at the KKU Herb-
arium, Department of Biology, Faculty of Science, Khon
Kaen University, Khon Kaen, Thailand. Chemicals and
most of the pure standards of phenolic acids were
purchased from Sigma-Aldrich Corporation (St. Louis,
MO, USA). The pure standards of m-hydroxybenzaldehyde
and p-hydroxybenzoic acid were purchased from Fluka
(Buchs, Switzerland) and Acros Organics (Geel, Belgium),
respectively.
Crude ethanolic extraction
Five grams of air-dried ground rhizome were macerated
and periodically stirred in 50 ml of absolute ethanol for
48 hours. The suspension was filtered through Whatman
No. 4 filter paper and centrifuged at 5,000 rpm for 15
minutes. The supernatant was air-dried to yield an
ethanolic crude extract. The residue was reconstituted in
dimethyl sulfoxide (DMSO) or ethanol before testing
and the solvent was used as a negative control.
Fractionated solvent extraction
Five grams of air-dried ground rhizome were macerated
and periodically stirred in 50 ml of hexane for 48 hours.
The suspension was filtered through the filter paper and
centrifuged at 5,000 rpm for 15 minutes. The super-
natant was air-dried to obtain the hexane soluble frac-
tion. The precipitate remaining from hexane extraction
was dispersed, macerated and periodically stirred in 50
mL of ethyl acetate for 48 hours. The ethyl acetate sus-
pension was filtered through the filter paper, centrifuged
at 5,000 rpm for 15 minutes, and air-dried to obtain the
ethyl acetate soluble fraction. The precipitate remaining
from ethyl acetate extraction was dispersed, macerated
and periodically stirred in 50 ml of methanol for 48
hours. The methanol suspension was filtered through
the filter paper, centrifuged at 5,000 rpm for 15 minutes,
and air-dried to obtain the methanol soluble fraction.
Each solvent fraction was reconstituted in an appropri-
ate vehicle, DMSO or ethanol, before testing.
Phenolic extraction
Phenolic extraction was performed by using acidic hy-
drolysis method [20] with some modifications. Briefly,
two hundred milliliters of 70% methanol were added to
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mixture was stirred for 2 hours at room temperature
and then filtered through the filter paper. The filtrate
was evaporated to 60 ml by a rotary evaporator. The
remaining filtrate was added with 50 ml of 2 M NaOH
and stirred continuously for 12 hours at room tempera-
ture. The mixture was centrifuged at 1,700 g for 20 mi-
nutes and then filtered through the filter paper. The
supernatant was repeatedly extracted three times with
80 ml of diethyl ether, in which the aqueous phase was
collected and the diethyl ether phase was discarded. The
aqueous phase was adjusted to pH 1.5 by 10 M HCl and
filtered through the filter paper. The filtrate was further
extracted by 80 ml of diethyl ether for three times, in
which the portion of the diethyl ether was collected. The
pooled diethyl ether phase was dehydrated with sodium
sulphate (Na2SO4) anhydrous and then filtered through
the filter paper. The filtrate was evaporated to 5 ml
using a rotary evaporator and finally evaporated to dry-
ness under a gentle stream of nitrogen.
Determination of total phenolic content
Total phenolic content in ethanolic crude extract was
determined by the Folin-Ciocalteu method as described
previously [21]. Gallic acid (Sigma) was used as the
standard and the result was calculated as μg Gallic Acid
Equivalent (GAE) per mg dry weight of the extract.
HPLC analysis of phenolic-rich extract
The identification of individual phenolic acids in phenolic-
rich extract prepared by phenolic extraction as described
above was carried out using a Waters HPLC system, based
on matching spectrum and retention times of phenolic
acid standards. The phenolic acid standards used were
gallic acid, protocatechuic acid, p-hydroxybenzoic acid,
vanillic acid, caffeic acid, syringic acid, m-hydroxy-
benzaldehyde, p-coumaric acid, ferulic acid, and sinapinic
acid. The HPLC system consisted of a Waters 600E
Multisolvent Delivery system, Waters In-Line degasser AF,
a Rheodyne injector with sample loop of 20 μl (180 μg of
the extract), and a Waters 2669 photodiode array (PDA)
detector. Empower software was used for data acquisition.
A Waters system column C18 (3.9 mm i.d. × 150 mm,
5 μm particle diameter) coupled to a guard column was
used. The temperature of the column was 25°C and the
flow rate of mobile phase was 1.0 ml/minute. The com-
pounds were eluted with a gradient elution of mobile
phase A (100% acetronitrile) and B (1% acetic acid in
deionized water) where A increased from 3% to 8% in
5 minutes, to 10% by 25 minutes and was maintained
at 10% for 20 minutes, then returned to initial condi-
tion (3%) in 10 minutes and remained for 5 minutes
before next injection. Elutes were detected by the PDA
detector at wavelength 280 nm.In vitro HDAC inhibition activity assay
HDAC inhibitory activity of the H. formicarum Jack. rhi-
zome extracts, sinapinic acid (Sigma) and sodium butyr-
ate (Sigma) was determined by using the Fluor-de-Lys
HDAC activity assay kit (Biomol, Enzo Life Sciences
International, Inc., Plymount Meeting, PA, U.S.A.). The
assay was performed according to the manufacturer’s in-
structions. Fluorescence was measured using a spectra
Max Gemini XPS microplate spectrofluorometer (Mo-
lecular Devices, Sunnyvale, CA, U.S.A.) with excitation
at 360 nm and emission at 460 nm. Inhibition of HDAC
activity was monitored by a decrease in fluorescence
signal.
Cell culture
HeLa and HT29 cells were obtained from the National
Cancer Institute, Bangkok, Thailand. Jurkat cells were
kindly provided by Dr. M. Leid (Oregon State University,
Oregon, U.S.A.). HCT116 and MCF-7 cells were kindly
provided by Dr. O. Tetsu (University of California, San
Francisco, U.S.A.). Vero cells were kindly provided by
Dr. S. Barusrux (Khon Kaen University, Khon Kaen,
Thailand). Cells were maintained in RPMI-1640 medium
supplemented with 10% fetal bovine serum, penicillin
(100 U/ml), and streptomycin (100 μg/ml) (Gibco-BRL).
The cells were incubated at 37°C in a humidified atmos-
phere with 5% CO2.
Antiproliferative activity assay
Cells were seeded in a 96-well plate at cell density of 104
cells/well and incubated for 24 hours. Sample groups were
treated with different concentrations of H. formicarum
Jack. rhizome extracts (0.5-3.0 mg/mL), sinapinic acid
(0.5-3.0 mM), or sodium butyrate (0.5-3.0 mM) for 24, 48
and 72 hours. Vehicle control groups were added with
DMSO (final concentration of 0.05%) or double distilled
water. Cell proliferation assays were performed using a
WST-8 Cell Proliferation Assay Kit (BioVision, Mountain
View, CA, U.S.A.) according to the manufacturer’s instruc-
tions. Absorbance (A) was measured at 415 nm using a
microtiter plate reader (Bio-Rad Laboratories, Hercules,
CA, U.S.A.). The absorbance at 655 nm was used as a ref-
erence wavelength. Cell proliferation or cell growth was
determined as a percentage of the vehicle control by an
equation of;
% Cell Proliferation ¼ control A‐sample Að Þ=controlA½ 
100:
Extraction of histone proteins
Cells grown in a 4.5-cm dish were treated with either
solvent control or the sample for 6 hours, and the his-
tone proteins were then isolated according to the
Figure 1 In vitro HDAC inhibitory activity of ethanolic crude
extract, solvent extraction fractions, and phenolic-rich extract.
The concentration of each sample in a reaction mixture was 200 μg/
50 μl. Results were expressed as relative HDAC activity with respect
to the vehicle control (DMSO). Sodium butyrate (NaB) was used as a
positive control. Each value represents the mean ± SD of three
experiments, performed in duplicate. Asterisks (*) denote significant
differences vs control (p < 0.05).
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with some modifications. In brief, cells were harvested
by trypsinization, washed with PBS, and then resus-
pended in Triton Extraction Buffer (TEB; PBS containing
0.5% (v/v) Triton X-100, 2 mM phenylmethylsulfonyl
fluoride, 0.02% (w/v) NaN3) at a cell density of 10
5 cells/
ml. The cells were incubated on ice and agitated periodic-
ally for 10 minutes. The suspension was centrifuged at
7,500 rpm for 10 minutes at 4°C to spin down the nuclei
and the supernatant was discarded. The nuclei pellet was
resuspended in 0.2 M HCl at a density of 106 nuclei/ml
and incubated overnight at 4°C. The suspension was
centrifuged at 7,500 rpm for 10 minutes at 4°C and the
supernatant containing histone proteins was collected.
Protein concentration was measured by using a Bio-Rad
protein assay kit (Bio-Rad Laboratories, Hercules, CA,
U.S.A.) based on the Bradford method.
Acid-Urea Triton X-100 polyacrylamide gel
electrophoresis (AUT-PAGE)
Inhibition on acetylation of cellular histones was ana-
lyzed by gel electrophoresis using acid urea/Triton-X-
100 (AUT) gels [22]. The upper gel consisted of 5%
acrylamide/bis-acrylamide containing 0.9 M acetic acid,
8 M urea. The resolving gel was 15% acrylamide/bis-
acrylamide containing 0.9 M acetic acid, 8 M urea, and
0.37% Triton X-100. The running buffer was 0.9 M
acetic acid. In this buffer system, positively charged pro-
teins migrate toward the cathode. Electrophoresis was
performed in a Mini PAGE System (Select BioProducts,
Edison, NJ, U.S.A.). Gels were pre-run at 150 volts for 4
hours at the ambient temperature. Wells were then
loaded with the second pre-run solution (1 M cyste-
amine (Sigma-Aldrich), 8 M urea, 0.9 M acetic acid) to
scavenge the residual free radicals and the gel was pre-
run at 150 volts for a further 40 minutes. Histone sam-
ples (5 μg histone protein) solubilized in loading buffer
(8 M urea, 10% glycerol, 0.9 M acetic acid, 5% β-
mercaptoethanol and 0.25% methylene blue) were boiled
for 5 minutes before being loaded and gels were run at
90 volts for 6 hours. Gels were silver-stained by using
PageSilver™ Silver Staining Kit (Fermentas, Burlington,
Ontario, Canada), dried, and photographed.
Apoptosis analysis
Apoptosis analysis was performed by using a Vybrant
Apoptosis Assay Kit #2 (Molecular Probes, Invitrogen
Corporation, Carlsbad, CA, U.S.A.) according to the
manufacturer’s instructions. Briefly, cells were seeded at
1.2 × 106 cells/4 ml in a 4.5-cm dish, incubated for 24
hours, and treated with different concentrations of the
extracts or sinapinic acid for 6 hours. Cells were
harvested by trypsinization, washed with cold PBS, and
resuspended in the Annexin-binding buffer. Cell densitywas determined and diluted in the annexin-binding buf-
fer to 105 cells per assay. Cells were incubated with
Alexa Fluor 488 Annexin V and Propidium iodide (PI) at
room temperature for 15 minutes. Following the incuba-
tion, cells were analyzed by flow cytometry using a
Beckman Coulter Cytomics FC500 MPL flow cytometry
(Beckman Coulter, Miami, FL, U.S.A.). The flow cytome-
try results were confirmed by viewing the cells under a
fluorescence microscope.
Statistical analysis
Data are expressed as means ± standard deviation (SD)
from three independent experiments. Tests for signifi-
cant differences between vehicle controls and sample
treated cells were carried out using one-way ANOVA
with Duncan’s post hoc test. The criterion for statistical
significance was set at p <0.05.
Results
In vitro HDAC inhibitory activity of the extracts from
H. formicarum Jack. rhizome
The effect of various polarity extracts including fraction-
ated solvent extracts from hexane soluble fraction, ethyl
acetate soluble fraction, methanol soluble fraction and
also ethanolic crude extract on in vitro HDAC activity
was examined by using HeLa nuclear extract as a source
of the HDAC enzymes. As shown in Figure 1, all of the
above mentioned extracts significantly inhibited HDAC
activity (p < 0.05). Among various polarity extracts
tested, ethanolic crude extract exhibited the most potent
HDAC inhibition of 55.2 ± 3.2% as compared to the
Figure 2 (See legend on next page.)
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Figure 2 HPLC profiles of phenolic-rich extract from H. formicarum Jack. rhizome. HPLC profiles of (A) phenolic-rich extract alone (180 μg),
(B) phenolic-rich extract added with the internal standard, m-hydroxybenzaldehyde (1 μg), and (C) phenolic-rich extract added with the internal
standard (1 μg) and the standard sinapinic acid (2 μg), are displayed comparatively. The data shown are representative of two independent
experiments performed in duplicate. A phenolic compound, sinapinic acid, is indicated and its chemical structure is depicted.
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the further effects of this plant on cancer cells.
Several lines of evidence indicate that some plant
phenolic compounds possess HDAC inhibitory activity
[16,18,19]. Therefore, we intended to investigate the ef-
fect of phenolic extract from H. formicarum Jack. rhi-
zome on HDAC activity in vitro. As expected, phenolic
extract of this plant significantly inhibited HDAC activ-
ity (p < 0.05), and its effect was comparable to that of
the ethanolic crude extract (Figure 1). The presence of
phenolic compounds in the ethanolic crude extract was
verified by the Folin-Ciocalteu reaction and total phen-
olic content was 316.28 ± 12.18 μg Gallic Acid Equiva-
lent (GAE)/mg dry weight. Because phenolic-rich extract
was found to possess HDAC inhibitory activity, there-
fore, this extract was also used to investigate the further
effects on cancer cells.
Sinapinic acid is a major phenolic acid of H. formicarum
Jack. rhizome possessing HDAC inhibitory activity
Some phenolic compounds were previously discovered
in the crude ethyl acetate extract of this plant [7], how-
ever, their HDAC inhibitory activity has not yet been ex-
plored. Preliminary separation and identification of
individual phenolic compounds in phenolic extract was
conducted by the reversed phase HPLC. Identification of
sample peaks by matching against retention time and
spectra of known phenolic standards under the sameFigure 3 In vitro HDAC inhibitory activity of sinapinic acid. Results we
control (DMSO). Sodium butyrate (NaB) at indicated concentrations was stu
experiments, performed in duplicate. Asterisks (*) denote significant differe
values represent concentrations of the indicated compounds that inhibit 5chromatographic conditions revealed that sinapinic acid
was one of the two major components of phenolic-rich
extract of H. formicarum Jack. rhizome (Figure 2A, 2B).
The confirmation of peak was obtained by the addition
of sinapinic acid standard into the sample for HPLC
analysis (Figure 2C). The yield of phenolic-rich extract
from 10 g of H. formicarum Jack. rhizome was 67.5 mg.
The amount of sinapinic acid was 3.4 μg/mg of phenolic-
rich extract. However, other sample peaks remained to be
identified. Interestingly, sinapinic acid was found to act as
HDAC inhibitor, blocking the enzyme activity in vitro with
an IC50 value (2.27 ± 0.13 mM) higher than that of the
well-known HDAC inhibitor sodium butyrate (0.97 ± 0.07
mM) (Figure 3). These findings suggest that sinapinic acid
takes account, at least in part, for the inhibition of HDAC
activity by the plant phenolic extract (Figure 1).
Ethanolic crude extract, phenolic-rich extract and
sinapinic acid inhibit HDAC activity in HeLa cells
HDAC inhibition by ethanolic crude extract, phenolic-
rich extract and sinapinic acid in HeLa cells was ana-
lyzed by AUT gel electrophoresis, whereby each cellular
core histone (H2A, H2B, H3, and H4) with different ex-
tent of acetylation can be separated. Herein, the profiles
of histones H4 and H2B extracted from ethanolic crude
extract-, phenolic-rich extract-, or sinapinic acid-treated
HeLa cells were demonstrated (Figure 4). The addition
of ethanolic crude extract and phenolic extract to cellre expressed as relative HDAC activity with respect to the vehicle
died comparatively. Each value represents the mean ± SD of three
nces vs control (p < 0.05). Half maximal inhibitory concentration (IC50)
0% of HDAC activity in vitro.
Figure 4 HDAC inhibitory activity of the plant extracts and sinapinic acid in HeLa cells. Effect of (A) ethanolic crude extract, phenolic-rich
extract and (B) sinapinic acid on histone acetylation in HeLa cells. After 6 h-treatment, the level of histone acetylation was determined by AUT
gel electrophoresis as described in Materials and Methods. Control (Cont) represents the level of histone acetylation in vehicle control treatment.
The sodium butyrate (NaB)-treatment was used as a positive control. The degree of histone acetylation of histone H4 is indicated as follows: 0,
nonacetylated; 1, monoacetylated; 2, diacetylated; 3, triacetylated; and 4, tetraacetylated. The data shown are representative of two independent
experiments performed in duplicate.
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histone H4 molecules, which could be detected clearly
on AUT gel (Figure 4A). The histone H4 with three acet-
ylated lysine residues was markedly increased when
treated the cells with ethanolic and phenolic-rich extracts
(Figure 4A). Similarly, treatment of HeLa cells with
sinapinic acid clearly increased di- and tri-acetylated H4
molecules with two and three acetylated lysine residues,
respectively (Figure 4B). However, HDAC inhibition of
sinapinic acid in the cell was much less effective when
compared to that of sodium butyrate. These observations
indicated that ethanolic crude extract, phenolic-rich ex-
tract and sinapinic acid inhibited HDAC activity not only
in vitro but also in the cells.
Effect of ethanolic crude extract, phenolic-rich extract and
sinapinic acid on proliferation of human cancer cell lines
The anticancer activity of the two rhizome extracts and
sinapinic acid was further investigated in 5 human can-
cer cell lines and in a non cancer cell line (Vero cells).
As shown in Table 1, ethanolic and phenolic-rich ex-
tracts possessing HDAC inhibitory activity inhibited the
growth of HeLa cells in a dose- and time-dependent
manner with IC50 values of 0.54 ± 0.03 and 0.30 ± 0.05
mg/ml, respectively, for exposure time of 72 hours.
Phenolic-rich extract showed greater antiproliferativeactivity than ethanolic crude extract on growth inhib-
ition of HeLa cells. However, both extracts showed no
significant activity on non cancer cells and other cancer
cell lines tested. Sinapinic acid significantly inhibited the
growth of HeLa cells with an IC50 value (0.91 ± 0.02
mM) lower than sodium butyrate (1.22 ± 0.03 mM) for
exposure time of 72 hours. Sinapinic acid also showed
greater antiproliferative activity than sodium butyrate on
HT29 cells. The antiproliferative activity of sinapinic
acid against HCT116 cells was not significantly different
from that of sodium butyrate. In contrast, sinapinic acid
showed a less efficient activity than sodium butyrate
against Jurkat cells. Further, both sinapinic acid and so-
dium butyrate showed no significant activity on non
cancer and breast cancer (MCF-7) cell lines. This finding
suggests that sinapinic acid may underpin, at least in
part, both the HDAC inhibitory activity and anticancer
activity of the rhizome extracts.
Induction of apoptosis by ethanolic crude extract,
phenolic extract and sinapinic acid in HeLa cells
Histone acetylation leads to modulation of expression of
a specific set of genes that result in cell cycle arrest and
induction of apoptosis [23,24]. HDAC inhibitors induce
apoptosis in a number of tumor cell types and through
various mechanisms [25]. To investigate the mechanism
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phenolic extract and sinapinic acid on HeLa cells, we ex-
amined their capacity to induce apoptosis. Apparently,
ethanolic crude extract, phenolic extract, and sinapinic
acid exhibited a significant effect on induction of apop-
tosis in HeLa cells even only 6 hours of exposure time
(Table 2). The treatment of HeLa cells with 1.4 mg/ml
of ethanolic and phenolic-rich extracts resulted in the
increase of early apoptotic cells up to 42.9% and 78.9%,
respectively. The treatment with 9 mM of sodium butyr-
ate and sinapinic acid resulted in the increase of early
apoptotic cells up to 7.6% and 8.4%, respectively. In con-
trast, the control HeLa cells had only 0.95% of apoptotic
cells. These results suggest that ethanolic crude extract
and phenolic extract, as well as sinapinic acid, suppress
the HeLa cell growth through induction of apoptosis.
Discussion
An expensive cost of cancer chemotherapy is a big prob-
lem for patients in developing countries. Therefore, an
alternative medicine for cancer treatment is still an inev-
itable option in low-income countries. While many poor
patients in these countries still struggle to save their life
with the use of traditional medicinal plants where most
of the plant’s active ingredients remains to be investi-
gated. To our knowledge, this is the first time that
sinapinic acid, a derivative of cinnamic acids, is identi-
fied as an HDAC inhibitor. However, HDAC inhibition
of sinapinic acid in the cell context was much less effective
than that of sodium butyrate. This might be due to the
greater difficulty of water soluble property of sinapinic
acid or there might be some structural changes during
transportation in a cell. Indeed, sinapinic acid has a parti-
tion coefficient (log P) value (log P = 1.52; ChemAxon)
greater than that of sodium butyrate (log P = 0.92;
ChemAxon), indicating its difficulty of water solubility
than sodium butyrate. The two methoxyl groups at C3
and C5 positions of sinapinic acid (Table 1) have little
influence on its hydrophobicity while the hydroxyl





















0.20 ± 0.14 3.55 ± 1.06 2.05 ± 0.92 4.15 ± 0.07 3.50
Cells labeled with Alexa Fluor 488 Annexin V and Propidium iodide (PI) after 6 h-treatm
three experiments performed in duplicate.hydrophobicity comparing to the prototype cinnamic acid
(log P = 2.14; ChemAxon).
In consistence with our results, it has been reported
that two other members of cinnamic acids, p-coumaric
acid and caffeic acid, possess in vitro HDAC inhibitory
activity [26], however, their HDAC inhibitory activity in
mammalian cells has not yet been reported. Further in-
vestigation on the role of various cinnamic acids in
HDAC inhibition and anticancer action would be of
interest to constitute a novel group of HDAC inhibitors.
Similar to HDAC inhibitors in the short-chain fatty acid
group [26,27], HDAC inhibitors of the proposed cinnamic
acid group seem to be effective at millimolar concentra-
tions in vitro. Since we observed HDAC inhibitory activity
in several polarity extracts tested (Figure 1), it is hopeful
that HDAC inhibitors other than sinapinic acid remain to
be identified from this plant.
A nuclear extract of HeLa cells was a rich source of
HDAC enzymes. Currently, eighteen HDACs have been
established in humans, and they are grouped into four
classes based on their homology to yeast HDACs, their
enzymatic activities and their subcellular localization
[9,24,27]. As shown in Figure 4A, a markedly increase in
tri-acetylated H4 molecules was observed after the cells
were treated with ethanolic crude extract and phenolic ex-
tract. This particular hyperacetylation pattern is different
from that of sodium butyrate- and sinapinic acid-induced
acetylated histone H4 (Figure 4B). This discrepancy may
be explained by a different sensitivity of specific HDAC(s)
to the inhibitor(s) [28] and/or a different mechanism, re-
versible or irreversible, of HDAC inhibition by the inhibi-
tors [27]. Further studies are needed to elucidate the
specificity of the above mentioned extracts and sinapinic
acid for individual HDAC family members.
Based on our findings that sinapinic acid possesses
antiproliferative activity more effective than a well-
known HDAC inhibitor sodium butyrate against HeLa
and HT29 cells (Table 1), one may envision a role for
sinapinic acid in a HDAC inhibitor-based cancer treat-
ment. Although antiproliferative activities of the plantpinic acid in HeLa cells
nolic-rich extract Sodium butyrate Sinapinic acid
mg/mL 1.4 mg/mL 4.5 mM 9.0 mM 4.5 mM 9.0 mM
0± 6.65 78.90 ± 5.09 3.75± 1.06 7.60 ± 1.27 4.40± 1.27 8.40± 1.55
± 1.84 4.15 ± 2.05 1.00 ± 0.28 2.05 ± 1.06 1.75 ± 0.78 3.25 ± 1.06
ent were analyzed by flow cytometry. Each value represents the mean ± SD of
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for a single-drug treatment, further investigation on the
use of sinapinic acid or the plant extracts in combination
with other anticancer drugs/medicinal plants may enable
the development of more effective therapeutic strategies.
The low efficient antiproliferative activity of the plant
extracts (Table 1) may be due to the presence of some
phenolic antioxidants [7]. Antioxidant activity of sinapinic
acid was observed at low concentrations [29], whereas its
antiproliferative activity was observed at higher concentra-
tions (Table 1). Despite its low efficient antiproliferative
activity, sinapinic acid possesses HDAC inhibitory activity
making it more attractive in combination chemotherapy.
In this regard, combining HDAC inhibitor vorinostat with
aurora kinase inhibitors enhances cancer cell killing [30],
and combining HDAC inhibitor sodium butyrate with
Doxorubicin potentiates apoptosis of myeloma cells [31].
Theoretically, our findings may validate the use of H.
formicarum Jack. rhizome extracts in combination with
other plant extracts as an alternative medicine for cancer
treatment [1-3].
Conclusions
The results in this report demonstrated that ethanolic
crude extract and phenolic-rich extract from H.
formicarum Jack. rhizome inhibited HDAC activity both
in vitro and in the cells. Sinapinic acid was identified as
the major component of phenolic extract, which may
underpin, at least in part, its HDAC inhibitory activity.
The growth inhibitory effect on a cervical cancer cell
line (HeLa cells) of ethanolic crude extract, phenolic ex-
tract and sinapinic acid is in accordance with their cap-
ability to induce cancerous cell apoptosis. Our findings
may validate the use of H. formicarum Jack. rhizome ex-
tracts as an alternative medicine for cancer treatment.
Further investigation, with details about chemical struc-
ture modification of sinapinic acid, HDAC inhibitory ac-
tivity, anticancer activity and combination with other
anticancer drugs, is of interest.
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